Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been given a consensus rating of “Moderate Buy” by the nine research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $9.43.

PYXS has been the topic of a number of recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 price objective (down from $10.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective (down from $7.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. Stephens initiated coverage on Pyxis Oncology in a report on Friday, November 8th. They issued an “overweight” rating and a $13.00 price objective for the company. Finally, William Blair cut Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st.

Insider Activity at Pyxis Oncology

In other news, CFO Pamela Ann Connealy bought 88,850 shares of the stock in a transaction on Tuesday, November 26th. The stock was purchased at an average price of $1.96 per share, for a total transaction of $174,146.00. Following the acquisition, the chief financial officer now owns 1,199,143 shares in the company, valued at approximately $2,350,320.28. This trade represents a 8.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 9.80% of the stock is owned by insiders.

Institutional Trading of Pyxis Oncology

A number of institutional investors have recently modified their holdings of PYXS. Jacobs Levy Equity Management Inc. acquired a new stake in Pyxis Oncology in the 3rd quarter valued at approximately $1,405,000. Bank of New York Mellon Corp lifted its position in shares of Pyxis Oncology by 92.2% in the second quarter. Bank of New York Mellon Corp now owns 311,630 shares of the company’s stock worth $1,031,000 after purchasing an additional 149,522 shares in the last quarter. abrdn plc boosted its holdings in Pyxis Oncology by 28.9% during the third quarter. abrdn plc now owns 913,045 shares of the company’s stock worth $3,351,000 after purchasing an additional 204,742 shares during the last quarter. Millennium Management LLC grew its position in Pyxis Oncology by 125.3% in the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock valued at $4,425,000 after purchasing an additional 743,499 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Pyxis Oncology by 5.5% in the third quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock valued at $3,982,000 after purchasing an additional 57,016 shares in the last quarter. 39.09% of the stock is currently owned by institutional investors.

Pyxis Oncology Trading Down 3.7 %

Pyxis Oncology stock opened at $1.55 on Tuesday. Pyxis Oncology has a 1 year low of $1.49 and a 1 year high of $6.85. The company’s 50-day moving average is $2.35 and its two-hundred day moving average is $3.09. The company has a market cap of $92.17 million, a PE ratio of -1.50 and a beta of 1.06.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.